Breaking News Instant updates and real-time market news.

AIMT

Aimmune

$21.05

-0.47 (-2.18%)

08:10
08/08/17
08/08
08:10
08/08/17
08:10

Aimmune announces publication of AR101 peanut allergy treatment data

Aimmune Therapeutics announced that its investigational treatment for peanut allergy, AR101, was highlighted in a recent publication by Benaroya Research Institute at Virginia Mason focused on the discovery of an immune cell subset, TH2A cells, that appears to be involved in the pathogenesis of allergies. These allergen-specific T cells are present in people with allergies but nearly entirely absent from people without allergies. The publication, which appeared in the August 2 issue of Science Translational Medicine, also reported that, in a small pilot experiment, AR101 treatment was associated with a significant reduction of TH2A cells in blood samples from a subset of peanut-allergic patients from Aimmune's ARC001 trial. AR101 is Aimmune's investigational biologic oral immunotherapy for desensitization of patients with peanut allergy. Benaroya Research Institute's work with the Aimmune samples potentially represents a new way to measure the allergy process and assess the effectiveness of specific treatments. In addition to the work on peanut allergy, the published article, "A phenotypically and functionally distinct human TH2 cell subpopulation is associated with allergic disorders," also reported on tests of allergies to grass and tree pollens, cat dander, dust mites, and mold, where TH2A played a pivotal role as well. The researchers found that these TH2A cells associated with stable allergic disease are terminally differentiated CD4+ T cells that exhibit several functional attributes that distinguish them from conventional TH2 cells.

  • 15

    Aug

AIMT Aimmune
$21.05

-0.47 (-2.18%)

03/22/17
PIPR
03/22/17
NO CHANGE
Target $38
PIPR
Overweight
Piper sees Aimmune as having regulatory advantage over DBV
After hosting investor meetings with management, Piper Jaffray analyst Charles Duncan keeps an Overweight rating on Aimmune (AIMT) with a $38 price target. While regulatory visibility will increase in the next 12 months, investors today should focus on response rates for the single highest tolerated dose, or how much peanut can an allergic person tolerate in a single exposure, Duncan tells investors in a research note. The analyst sees Aimmune's AR101 as having generated "uniquely impressive results" on the two key efficacy measures relative to DBV Technologies (DBVT), including both response rates and size of highest tolerated dose. He believes investors may be overlooking catalysts for Aimmune, including up-dosing progress from the PALISADE trial prior to Phase III results around year-end.
02/17/17
PIPR
02/17/17
NO CHANGE
Target $40
PIPR
Overweight
Piper sees Aimmune trial changes as reducing clinical risk
Piper Jaffray analyst Charles Duncan believes the Phase III change announced yesterday by Aimmune Therapeutics (AIMT) reduces clinical risk for the trial read-out, while still addressing a broad group of children and teens more broadly relative to Aimmune's "mindshare competitor" DBV Technologies (DBVT). The PALISADE Phase III primary analysis and initial BLA application will now include ages 4-17, but exclude adult patients, Duncan tells investors in a research note. Following the news, the analyst still believes Aimmune's AR101 will be approved and used in some of adult patients, but points out another trial may be required. He pushed his first AR101 sales estimate in adults back by two years to 2021 in the U.S. market and 2020 to 2022 in the E.U. market. Duncan keeps an Overweight rating on Aimmune with a $40 price target.
12/21/16
PIPR
12/21/16
NO CHANGE
PIPR
Piper lays out top BioPharma picks for 2017
Piper Jaffray analysts laid out their top BioPharma picks for 2017. Analyst Richard Purkiss favors Pfizer (PFE) and Eli Lilly (LLY) as his top large pharma picks. Analyst Joshua Schimmer calls Gilead (GILD) and Alexion (ALXN) his top large cap picks. Analyst David Amsellem names Horizon Pharma (HZNP) his top specialty pharma pick. Piper's other top Biopharma picks for 2017 include ACADIA (ACAD), Aimmune (AIMT), Akorn (AKRX), Alnylam (ALNY), Axovant Sciences (AXON), Cara Therapeutics (CARA), CoLucid Pharmaceuticals (CLCD), Eale Pharmaceuticals (EGRX), Exelixis (EXEL), Ionis Pharmaceuticals (IONS), Mallinckrodt (MNK), Neurocrine (NBIX), Nektar (NKTR), Otonomy (OTIC), Reata Pharmaceuticals (RETA), Rigel Pharmaceuticals (RIGL), Ignyta (RXDX), Theravance Biopharma (TBPH), Versartis (VSAR) and Voyager Therapeutics (VYGR). The analysts look for recent momentum in BioPharma to continue in 2017. They believe innovation and potentially repatriation should lead to increased merger activity.
09/26/16
JMPS
09/26/16
INITIATION
Target $30
JMPS
Outperform
Aimmune initiated with an Outperform at JMP Securities
JMP Securities analyst Liisa Bayko initiated Aimmune with an Outperform and a $30 price target. The analyst is confident that AR101 Phase 3 data will show meaningful desensitization to peanuts in allergic children and adults and we will be paying close attention to safety and any discontinuations and projects $1.4B in sales by 2028.

TODAY'S FREE FLY STORIES

ZAGG

Zagg

$15.65

-0.15 (-0.95%)

09:21
09/24/18
09/24
09:21
09/24/18
09:21
Recommendations
Zagg analyst commentary  »

Zagg to benefit from…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$162.90

-3.16 (-1.90%)

09:21
09/24/18
09/24
09:21
09/24/18
09:21
Periodicals
Facebook appoints Ajit Mohan as India managing director, The Times of India says »

Facebook has appointed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Oct

  • 07

    Nov

ABMD

Abiomed

$384.69

2.74 (0.72%)

09:20
09/24/18
09/24
09:20
09/24/18
09:20
Conference/Events
Abiomed to hold an investor breakfast meeting »

Annual Investor…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

  • 27

    Nov

BECN

Beacon Roofing

$39.38

-0.53 (-1.33%)

, OC

Owens Corning

$58.26

-0.34 (-0.58%)

09:18
09/24/18
09/24
09:18
09/24/18
09:18
Recommendations
Beacon Roofing, Owens Corning, Carlisle analyst commentary  »

Roofing estimates lowered…

BECN

Beacon Roofing

$39.38

-0.53 (-1.33%)

OC

Owens Corning

$58.26

-0.34 (-0.58%)

CSL

Carlisle

$123.80

-0.345 (-0.28%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

  • 25

    Sep

  • 29

    Sep

SPX

S&P 500

$0.00

(0.00%)

, VIX

Volatility Index S&P 500 Options

$0.00

(0.00%)

09:18
09/24/18
09/24
09:18
09/24/18
09:18
Options
Overnight activity included 134 trades in SPX and 8 trades in VIX »

134 trades were executed…

SPX

S&P 500

$0.00

(0.00%)

VIX

Volatility Index S&P 500 Options

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

QURE

uniQure

$38.40

-2.7 (-6.57%)

09:17
09/24/18
09/24
09:17
09/24/18
09:17
Recommendations
uniQure analyst commentary  »

uniQure price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Oct

  • 03

    Oct

FTV

Fortive

$86.97

-0.45 (-0.51%)

, AIMC

Altra Industrial Motion

$43.10

0.45 (1.06%)

09:17
09/24/18
09/24
09:17
09/24/18
09:17
Hot Stocks
Fortive sets final exchange ratio in split-off exchange offer »

Fortive Corporation (FTV)…

FTV

Fortive

$86.97

-0.45 (-0.51%)

AIMC

Altra Industrial Motion

$43.10

0.45 (1.06%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

QURE

uniQure

$38.40

-2.7 (-6.57%)

09:16
09/24/18
09/24
09:16
09/24/18
09:16
Hot Stocks
uniQure says third patient has been treated in AMT-061 study »

uniQure announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Oct

  • 03

    Oct

NVDA

Nvidia

$263.44

-2.83 (-1.06%)

09:16
09/24/18
09/24
09:16
09/24/18
09:16
Recommendations
Nvidia analyst commentary  »

Mixed reaction to Nvidia…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 26

    Sep

  • 27

    Sep

  • 10

    Dec

TSLA

Tesla

$299.05

0.73 (0.24%)

09:16
09/24/18
09/24
09:16
09/24/18
09:16
Recommendations
Tesla analyst commentary  »

Tesla Model 3 production…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 29

    Oct

DNB

Dun & Bradstreet

$143.01

-0.26 (-0.18%)

09:16
09/24/18
09/24
09:16
09/24/18
09:16
Hot Stocks
Dun & Bradstreet announce expiration of 'Go Shop' period »

Dun & Bradstreet…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NBIX

Neurocrine

$119.85

-0.31 (-0.26%)

09:15
09/24/18
09/24
09:15
09/24/18
09:15
Conference/Events
Neurocrine has a conference call hosted by JPMorgan »

JPMorgan Analyst Rama…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

AAPL

Apple

$217.65

-2.35 (-1.07%)

, CRM

Salesforce

$155.46

-0.07 (-0.05%)

09:14
09/24/18
09/24
09:14
09/24/18
09:14
Hot Stocks
Apple, Salesforce announce strategic partnership »

Apple and Salesforce…

AAPL

Apple

$217.65

-2.35 (-1.07%)

CRM

Salesforce

$155.46

-0.07 (-0.05%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

  • 25

    Sep

  • 26

    Sep

  • 26

    Sep

  • 03

    Mar

HAFC

Hanmi Financial

$25.65

-0.45 (-1.72%)

09:14
09/24/18
09/24
09:14
09/24/18
09:14
Conference/Events
Goldman Sachs to hold a conference »

9th Annual Regional &…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

  • 07

    Nov

CMTL

Comtech

$33.32

0.5 (1.52%)

09:11
09/24/18
09/24
09:11
09/24/18
09:11
Hot Stocks
Comtech receives $9.1M contract to supply troposcatter equipment to Iraqi Navy »

Comtech…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

STM

STMicroelectronics

$18.83

-0.22 (-1.15%)

09:10
09/24/18
09/24
09:10
09/24/18
09:10
Hot Stocks
STMicroelectronics, Leti announce cooperation to develop GaN-on-Silicon tech »

STMicroelectronics and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

09:10
09/24/18
09/24
09:10
09/24/18
09:10
General news
FX Action: USD-CAD »

FX Action: USD-CAD…

CMCSA

Comcast

$37.91

0.1 (0.26%)

, DIS

Disney

$110.72

-0.9 (-0.81%)

09:09
09/24/18
09/24
09:09
09/24/18
09:09
Hot Stocks
Fly Intel: Pre-market Movers »

HIGHER: Disney (DIS), up…

CMCSA

Comcast

$37.91

0.1 (0.26%)

DIS

Disney

$110.72

-0.9 (-0.81%)

FOXA

21st Century Fox

$44.33

-0.26 (-0.58%)

AMRN

Amarin

$3.00

0.06 (2.04%)

EPZM

Epizyme

$10.30

-0.1 (-0.96%)

P

Pandora

$9.08

-0.31 (-3.30%)

SIRI

Sirius XM

$6.97

-0.05 (-0.71%)

GOLD

Randgold

$63.94

-0.64 (-0.99%)

ABX

Barrick Gold

$10.48

-0.135 (-1.27%)

XON

Intrexon

$14.50

-0.035 (-0.24%)

NTNX

Nutanix

$46.55

-1.43 (-2.98%)

BILI

Bilibili

$12.47

-0.93 (-6.94%)

ANAB

AnaptysBio

$92.83

0.61 (0.66%)

CMCSK

Comcast

$0.00

(0.00%)

FOX

21st Century Fox

$43.97

-0.23 (-0.52%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

  • 24

    Sep

  • 24

    Sep

  • 24

    Sep

  • 24

    Sep

  • 24

    Sep

  • 27

    Sep

  • 01

    Oct

  • 02

    Oct

  • 22

    Oct

  • 24

    Oct

  • 25

    Oct

  • 29

    Oct

  • 10

    Dec

IMPV

Imperva

$45.65

-0.6 (-1.30%)

, FIVN

Five9

$43.21

-1.32 (-2.96%)

09:07
09/24/18
09/24
09:07
09/24/18
09:07
Conference/Events
Microsoft to hold a conferenc e »

Microsoft Ignite will be…

IMPV

Imperva

$45.65

-0.6 (-1.30%)

FIVN

Five9

$43.21

-1.32 (-2.96%)

CDAY

Ceridian

$42.07

-0.855 (-1.99%)

MSFT

Microsoft

$114.70

1.13 (0.99%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

  • 25

    Sep

  • 21

    Oct

  • 24

    Oct

  • 25

    Oct

  • 28

    Oct

  • 06

    Nov

  • 28

    Nov

  • 03

    Mar

MNKD

MannKind

$1.71

0.02 (1.18%)

09:07
09/24/18
09/24
09:07
09/24/18
09:07
Hot Stocks
MannKind completes cohort 1, opens enrollment of cohort 2 for Afrezza study »

MannKind announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Oct

CZR

Caesars

$10.78

-0.175 (-1.60%)

09:07
09/24/18
09/24
09:07
09/24/18
09:07
Hot Stocks
Caesars names Monica Digilio as Chief Human Resources Officer »

Caesars Entertainment…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SRPT

Sarepta

$147.81

-5.105 (-3.34%)

09:06
09/24/18
09/24
09:06
09/24/18
09:06
Recommendations
Sarepta analyst commentary  »

Sarepta price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GPRO

GoPro

$6.46

-0.05 (-0.77%)

, CMCSA

Comcast

$37.91

0.1 (0.26%)

09:05
09/24/18
09/24
09:05
09/24/18
09:05
Periodicals
Tile names GoPro vet CJ Prober CEO, adds Comcast as investor, TechCrunch says »

Tile is appointing CJ…

GPRO

GoPro

$6.46

-0.05 (-0.77%)

CMCSA

Comcast

$37.91

0.1 (0.26%)

CMCSK

Comcast

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CNBX

Cannabics Pharmaceuticals

$0.00

(0.00%)

09:04
09/24/18
09/24
09:04
09/24/18
09:04
Syndicate
Cannabics Pharmaceuticals raises $7.5M in a registered direct offering »

Cannabics Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DGX

Quest Diagnostics

$107.62

-0.32 (-0.30%)

09:03
09/24/18
09/24
09:03
09/24/18
09:03
Recommendations
Quest Diagnostics analyst commentary  »

Quest Diagnostics price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.